Browsing by Author "Siddiqui, Meraj Alam"

Now showing 1 - 5 of 5

Clinical Features and Outcomes Following SARS-cov-2 Infection in Pediatric Liver Transplant Patients
(2022) Siddiqui, Meraj Alam; Bakirci, Oguz; Donger, Utku; Warasnhe, Khaled; Ozcay, Figen; 0000-0002-5739-6590; 0000-0002-5214-516X; ABF-7609-2022; ABG-5684-2020
Eculizumab Therapy for Late Antibody-Mediated Rejection in Pediatric Kidney Transplant Patients
(2022) Siddiqui, Meraj Alam; Baskin, Esra; Karakayali, Feza Yarbug; Gemici, Atilla; Gulleroglu, Kaan; Yilmaz, Aysun Caltik; Moray, Gokhan; Haberal, Mehmet; 0000-0003-1434-3824; 0000-0002-3462-7632; AAJ-8833-2021; AAJ-8097-2021
Preoperative Systemic Immune-Inflammation Index, Platelet-Lymphocyte Ratio and Neutrophil-Lymphocyte Ratio in Predicting the Delayed Graft Function in Pediatric Renal Transplant Recipients: A Single Centre Study
(2022) Baskin, Esra; Siddiqui, Meraj Alam; Gulleroglu, Kaan Savas; Yilmaz, Aysun Caltik; Akdur, Aydincan; Moray, Gokhan; Haberal, Mehmet; 0000-0003-1434-3824; 0000-0002-5739-6590; 0000-0002-3462-7632; AAJ-8833-2021; ABF-7609-2022; AAJ-8097-2021
The Role of Platelet-Lymphocyte Ratio and Neutrophil-Lymphocyte Ratio in Predicting the Delayed Graft Function in Pediatric Renal Transplant Patients
(2022) Siddiqui, Meraj Alam; Baskin, Esra; Gulleroglu, Kaan Savas; Yilmaz, Aysun Caltik; Moray, Gokhan; Haberal, Mehmet; 0000-0003-1434-3824; 0000-0002-5739-6590; 0000-0003-0774-4419; 0000-0002-3462-7632; 35570615; AAJ-8833-2021; ABF-7609-2022; AAD-1877-2021; AAJ-8097-2021
Objectives: Delayed graft function is a common adverse outcome after renal transplant. Attempts for early prediction and prevention of delayed graft function are often challenging and misleading. Herein, we investigated for the first time the correlation between delayed graft function and preoperative noninvasive hematologic parameters to predict the possible adverse outcomes for renal transplant in pediatric patients. Materials and Methods: In this study, preoperative hematologic parameters of 51 pediatric renal transplant recipients followed between 2015 and 2021 were analyzed retrospectively. The selected 16 renal transplant patients with delayed graft function and 35 patients without delayed graft function had no concomitant comorbidities. The cutoff values for platelet-to-lymphocyte ratio of <5 and neutrophil-to-lymphocyte ratio of <175 were considered low. Results: We retrospectively evaluated a total of 51 (male/female, 33/18) pediatric kidney transplant recipients with a median age of 12 (interquartile range, 8-18) years. Median level of circulating lymphocytes was significantly higher in patients with delayed graft function compared with patients without delayed graft function (2 vs 1, P = .040). The preoperative low values for platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio were more prevalent in recipients who developed delayed graft function versus those who did not develop delayed graft function (68.8% vs 31.4% [P = .014] and 68.8% vs 34.3% [P = .023], respectively). Conclusions: Pretransplant low platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte were associated with increased number of delayed graft dysfunction. These novels and noninvasive inflammatory biomarkers may contribute to an early prediction of delayed graft function in pediatric kidney transplant recipients.
Use of Eculizumab in Pediatric Patients with Late Antibody-Mediated Rejection After Kidney Transplantation
(2022) Siddiqui, Meraj Alam; Baskin, Esra; Karakayali, Feza Yarbug; Gemici, Atilla; Gulleroglu, Kaan; Yilmaz, Aysun Caltik; Moray, Gokhan; Haberal, Mehmet; 0000-0002-3462-7632; 0000-0003-0774-4419; 0000-0003-1434-3824; 0000-0002-5739-6590; 35570600; AAJ-8097-2021; AAD-1877-2021; AAJ-8833-2021; ABF-7609-2022
Late antibody-mediated rejection triggered by donor-specific antibodies is a leading cause of kidney allograft failure. Effective treatment options for late antibody-mediated rejection are limited in renal transplant recipients. Here, we report 2 pediatric cases of severe late antibody-mediated rejection resistant to conventional immunosuppressive therapy who were successfully treated with eculizumab. Two patients who fulfilled the late antibody-mediated rejection diagnostic criteria (positive donor-specific antibodies, elevated mean fluorescence index, acute and/or chronic morphological lesions in the microvasculature, and abnormal kidney function test) were included in this study. Both patients were previously unsensitized with negative panel-reactive antibody. Case 1 was a 12-year-old male patient with kidney failure secondary to vesicoureteral reflux who underwent related-living donor kidney transplantation 2 years ago. Eleven months later, he was diagnosed with late antibody-mediated rejection. Despite an aggressive conventional immunosuppressive regimen, signs of rejection persisted. After the patient was treated with 2 doses of eculizumab, his mean fluorescence index dropped and serum creatinine decreased from 3.8 to 1.5 mg/dL. Case 2 was an unsensitized 16-year-old male patient with kidney failure secondary posterior urethral valve who underwent related-living donor kidney transplantation 4 years ago. Two years later, he was diagnosed with late antibody-mediated rejection. Despite an aggressive conventional immunosuppressive regimen, signs of rejection persisted. After treatment with 2 doses of eculizumab, his mean fluorescence index dropped and serum creatinine decreased from 2.1 to 1.01 mg/dL. In both patients, eculizumab therapy effectively reduced the markers of late antibody-mediated rejection and improved the kidney function.